The FDA Wants to Build Drug Factories Inside Hospitals
The FDA proposed a new rule that could let drug manufacturers register entire networks of modular production units as a single facility. For cell and gene therapies, it's the regulatory foundation for a future where your cancer treatment gets made down the hall, not across the country.
Right now, if you need a CAR-T therapy (a cancer treatment made from your own re-engineered immune cells), here's what happens. A doctor draws your blood. It gets frozen. Then it's shipped across the country, sometimes across an ocean, to one of a handful of specialized factories. Weeks later, your custom-built treatment ships back, still frozen, through a fragile cold chain that costs a fortune and can fail at any step.
It's like ordering a pizza that has to be flown to Italy, baked in one specific oven, then flown back to your table. Cold.
The FDA just proposed blowing up that model entirely.
One Rule to Connect Them All
On July 13, the agency published a proposed rule in the Federal Register that would create a brand-new regulatory category: the distributed manufacturing establishment, or DME. Think of it as a hub-and-spoke system for making drugs and biologics. One central quality hub oversees a network of identical manufacturing units scattered across different locations, potentially inside hospitals, near patients, wherever they're needed most.
The big deal: the entire network could register as a single establishment instead of each site filing separately. That sounds like paperwork reform, but it's actually a seismic shift. Under the old rules, every manufacturing site needed its own registration, its own inspections, its own regulatory headaches. Adding a new location meant navigating a bureaucratic obstacle course.
Under the proposed framework, units can be added, relocated, or removed through streamlined updates. The FDA just needs advance notice. It's the difference between buying a new house every time you move versus updating your address with the post office.
Why Cell and Gene Therapy Desperately Needs This
The timing isn't accidental. Cell and gene therapies are booming, but manufacturing hasn't kept up. These treatments often require one batch per patient, made from that patient's own cells. You can't scale up a single factory the way you would for a blockbuster pill. You have to scale out, running hundreds of tiny parallel batches.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
And the current centralized model is buckling under the pressure.
Manufacturing is still dominated by manual, open-handling steps that are slow, expensive, and prone to contamination. Building a single GMP-compliant facility (the kind of ultra-clean environment regulators require) takes massive capital investment and years of construction. There aren't enough of them, and the skilled workers to staff them are in short supply.
The result? Patients wait weeks for treatments. Doses cost hundreds of thousands of dollars. Access depends heavily on geography; if you live near a major medical center, your odds are better.
The Vision: Manufacturing at the Bedside
The FDA's proposal isn't just about registration paperwork. It's the structural foundation for something much bigger: near-patient manufacturing.
Imagine a standardized, automated manufacturing pod sitting inside a hospital. A patient's cells get collected down the hall, processed on-site in a closed system, and infused back into the patient within days instead of weeks. No cross-country shipping. No cryogenic logistics nightmares. No prayers that FedEx doesn't lose your cancer treatment.
Several companies are already building the hardware to make this real. KeyPlants, a Swedish firm, offers portable pod facilities for cell therapy and viral vector production that can be operational in weeks. The ARMI/FDA BioFoundry project is developing a scalable, modular, automated, and closed (SMAC) platform explicitly designed for cell therapies, gene therapies, and tissue-engineered products. Cytiva's FlexFactory provides turnkey modular plants using single-use technology.
The equipment is getting there. What's been missing is the regulatory architecture to support it.
The Fine Print Matters
The proposed rule has some important guardrails. To qualify as a DME, all manufacturing units in the network must be equivalent in design and operation. They all sit under one unified quality system run by the central hub. And at least one unit must be movable (or there must be at least two fixed units).
For biologics, the marketing application (a BLA, in regulatory speak) would need to describe the entire decentralized manufacturing strategy: how units are designed, how quality is controlled, how consistency is maintained across sites.
The rule also tightens oversight of foreign manufacturing sites in the supply chain, including those making viral vectors, plasmids, and other starting materials that feed into advanced therapies. This piece aligns with the PREVENT Pandemics Act and reflects hard lessons from COVID-era supply disruptions.
Comments on the proposed rule are open until September 11, 2026. It's not final yet, and details could change.
What's Still Missing
Let's be clear: this proposed rule is a foundation, not a finished building. It solves the "who registers and how" question. But several critical pieces remain unresolved.
Process validation is a big one. Before approving a drug, the FDA needs proof that your manufacturing process reliably produces a consistent product. How do you validate that across dozens of hospital-based pods? The agency hasn't fully answered that yet.
Inspections are another puzzle. The FDA traditionally inspects each manufacturing facility individually. If your network has 50 units in 50 hospitals, does every site get an inspector? The logistics get complicated fast.
The FDA's FRAME initiative (Framework for Regulatory Advanced Manufacturing Evaluation) is working on guidance for these questions, including how standard manufacturing quality rules apply to distributed setups. Draft guidance covering biologics and advanced technologies has been announced but not yet published.
Meanwhile, the agency has already been loosening CMC requirements (the chemistry, manufacturing, and controls rules) specifically for cell and gene therapies. Earlier this year, the FDA updated guidance offering flexible approaches to quality oversight for these products, including relaxed expectations around process validation lot numbers and release specifications.
The Bigger Picture
Zoom out and the strategic intent becomes clear. The FDA is building a regulatory framework for a future where drug manufacturing looks less like a centralized factory and more like a distributed network: modular, automated, digitally connected, deployable anywhere.
For cell and gene therapies, this could be transformative. The vein-to-vein supply chain (from blood draw to treatment infusion) could shrink from weeks to days. Costs could drop as manual steps get automated and shipping logistics simplify. And patients in rural areas or developing countries could finally access treatments that are currently reserved for those near elite medical centers.
We're not there yet. The proposed rule needs to survive the comment period and get finalized. The companion guidance on quality and manufacturing standards needs to actually ship. And the modular manufacturing platforms need to prove they can deliver consistent, safe products across a distributed network.
But for the first time, the regulatory scaffolding is going up. The FDA just told the biotech industry: we see where this is going, and we're building the rules to let it happen.
Funding & Financings
5 min read
The Bet to Dethrone Immunology's Biggest Cash Cow
A three-year-old biotech just filed to go public with plans to take on Dupixent, immunology's $18 billion juggernaut. Attovia Therapeutics has $255 million in venture backing, miniaturized antibodies, and a very long road ahead.
